Details of the Drug Reposition

General Information of This Drug (ID: DMD2WPG)

Drug Name
TRIENTINE   DMD2WPG
Synonyms
Trientine HCl; 21121-06-2; triethylenetetramine HCl; SMR000058543; AC1NUQ0M; MLS000069683; SCHEMBL205201; CHEMBL1200783; CTK0I9735; DTXSID80419994; XPVOJYDIBHYVFL-UHFFFAOYSA-N; Pharmakon1600-01505675; NSC759164; NSC158271; AKOS027276425; NSC-158271; NSC-759164; 1, N,N'-bis(2-aminoethyl)-, tetrahydrochloride; 1,2-Ethanediamine, N,N'-bis(2-aminoethyl)-, hydrochloride; N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine hydrochloride
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Renal cell carcinoma DISQZ2X8 2C90 Discontinued in Phase 2 [1]
Inborn error of metabolism DISO5FAY 5C50-5C59 Discontinued in Phase 2 [2]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Wilson disease DISVS9H7 5C64.00 Investigative [3]
------------------------------------------------------------------------------------

References

1 Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects
2 Sublingual Methadone for the Management of Cancer-related Procedure Pain in Inpatients
3 Trientine FDA Label